Evercore ISI initiated coverage on MindMed with a new price target
$MNMD
Medicinal Chemicals and Botanical Products
Health Care
Evercore ISI initiated coverage of MindMed with a rating of Outperform and set a new price target of $23.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/28/2025 | $23.00 | Outperform | Evercore ISI |
| 12/20/2024 | $20.00 | Buy | Chardan Capital Markets |
| 10/14/2024 | $20.00 | Outperform | Leerink Partners |
| 7/24/2024 | $36.00 | Buy | ROTH MKM |
| 5/29/2024 | $27.00 | Outperform | Robert W. Baird |
| 4/15/2024 | $20.00 | Outperform | Leerink Partners |
| 12/5/2023 | $9.00 | Buy | Canaccord Genuity |
| 12/9/2022 | $25.00 | Buy | ROTH Capital |
Evercore ISI initiated coverage of MindMed with a rating of Outperform and set a new price target of $23.00
Chardan Capital Markets initiated coverage of MindMed with a rating of Buy and set a new price target of $20.00
Leerink Partners resumed coverage of MindMed with a rating of Outperform and set a new price target of $20.00
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief Financial Officer (CFO), effective June 2, 2025. In her new role, Ms. Roberts will join MindMed's executive leadership team where she will oversee all aspects of financial strategy, capital planning, accounting, investor relations and information technology as the Company advances its clinical development and commercial priorities for its lead product candidate MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer (CCO). In his new role, Mr. Wiley will serve as a member of the executive team, overseeing the Company's commercial vision and strategy as it prepares for the potential launch of its first product, MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive innovation and growth of MindMed's R&D operations as the Company prepares to initiate three Phase 3 studies of MM120 orally disintegrating tablet (ODT) in generalized anxiety disorder and major depressive disorder. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203094211/en/Javier Muniz,